|Articles|November 23, 2011

Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin

Author(s)Pharmaceutical Technology Editors

FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin.

FDA Commissioner Margaret Hamburg held a special press briefing last week on Genentech’s Avastin drug and its indications for metastatic breast cancer. She announced that the agency is revoking that indication based on FDA follow-up studies which did not show promising results. See related blog and press release.

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

October 2nd, 2026

Regulatory Roundup—September 2026

The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.

October 1st, 2026

Drapeau’s AI Deep Dive: The Control Lab Tested for Flavor

Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.

October 1st, 2026

Q&A: USP CEO Urges Manufacturers to Act Now to Stop Drug Shortages

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

September 30th, 2026

CPHI Milan: Why One Reliable Supplier Isn't Enough

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com

September 28th, 2026

CPHI Milan 2026: Digital Supply Chains

Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.

FDA approves once-daily tavapadon, the first selective D1/D5 agonist for adults with Parkinson's

September 28th, 2026

Tavapadon Sets Development Benchmark for Parkinson's

FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.

Merck's $2.13B KRAS G12D license moves tech transfer and supply planning into the preclinical stage.

September 28th, 2026

KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer

Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.

September 28th, 2026

CPHI Milan: How USP Will Shape Procurement Decisions

Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.

Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin

Related to this article

Trending on Pharmaceutical Technology

Regulatory Roundup—September 2026

Drapeau’s AI Deep Dive: The Control Lab Tested for Flavor

ABO2203's $7.2B Milestones Signal RNA Capacity Demand

Q&A: USP CEO Urges Manufacturers to Act Now to Stop Drug Shortages

Companies Launching Equipment and Services at CPHI Milan 2026